Mesoblast Ltd (MESO) stock
MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30
$11.91−0.54 (-4.34%)
Close on Nov 17, 2026Market cap $1.54BP/E –Yield –
Mesoblast profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Mesoblast's profit margin for the twelve months ending Jun 30, 2023 was -1091.7%. For fiscal 2026 it was -47.8%, against -593.9% the year before. The highest annual figure on record is -9.7% in fiscal 2016.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -47.8% | +546.1 |
| FY2025 | Jun 30, 2025 | -593.9% | +896.4 |
| FY2024 | Jun 30, 2024 | -1490.3% | −398.6 |
| FY2023 | Jun 30, 2023 | -1091.7% | −197.1 |
| FY2022 | Jun 30, 2022 | -894.6% | +434.6 |
| FY2021 | Jun 30, 2021 | -1329.2% | −1086.8 |
| FY2020 | Jun 30, 2020 | -242.4% | +294.6 |
| FY2019 | Jun 30, 2019 | -537.0% | −333.5 |
| FY2018 | Jun 30, 2018 | -203.5% | +2981.2 |
| FY2017 | Jun 30, 2017 | -3184.7% | −3175.0 |
| FY2016 | Jun 30, 2016 | -9.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -1024.7% | −60.0 |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -959.3% | +100.0 |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -1147.4% | −58.7 |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -1123.4% | −493.3 |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -964.7% | +153.4 |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -1059.3% | +325.3 |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -1088.8% | +57.7 |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -630.1% | +1250.7 |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -1118.1% | +3533.8 |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -1384.6% | −1259.5 |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -1146.5% | −32.0 |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -1880.8% | −1848.6 |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -4651.9% | −3598.2 |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -125.1% | +1874.1 |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -1114.4% | +201.3 |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -32.2% | +135.4 |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -1053.7% | +171.8 |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -1999.2% | −23.8 |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -1315.7% | −1418.0 |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -167.6% | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -1225.5% | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -1975.4% | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | 102.3% | – |
See a number that looks wrong?